| Reversal of indoleamine 2, 3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme TA Triplett, KC Garrison, N Marshall, M Donkor, J Blazeck, C Lamb, ... Nature biotechnology 36 (8), 758-764, 2018 | 232 | 2018 |
| hBUB1 defects in leukemia and lymphoma cells HY Ru, RL Chen, WC Lu, JH Chen Oncogene 21 (30), 4673-4679, 2002 | 86 | 2002 |
| Trans-activation of heparanase promoter by ETS transcription factors WC Lu, YN Liu, BB Kang, JH Chen Oncogene 22 (6), 919-923, 2003 | 79 | 2003 |
| Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display KC Chen, CH Wu, CY Chang, WC Lu, Q Tseng, ZM Prijovich, ... Chemistry & biology 15 (12), 1277-1286, 2008 | 39 | 2008 |
| Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity WC Lu, A Saha, W Yan, K Garrison, C Lamb, R Pandey, S Irani, A Lodi, ... Proceedings of the National Academy of Sciences 117 (23), 13000-13011, 2020 | 35 | 2020 |
| In vitro selection of proteins via emulsion compartments WC Lu, AD Ellington Methods 60 (1), 75-80, 2013 | 33 | 2013 |
| Directed evolution of the substrate specificity of biotin ligase WC Lu, M Levy, R Kincaid, AD Ellington Biotechnology and bioengineering 111 (6), 1071-1081, 2014 | 26 | 2014 |
| ECSTASY, an adjustable membrane-tethered/soluble protein expression system for the directed evolution of mammalian proteins CP Chen, YT Hsieh, ZM Prijovich, HY Chuang, KC Chen, WC Lu, Q Tseng, ... Protein Engineering, Design & Selection 25 (7), 367-375, 2012 | 21 | 2012 |
| Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing C McGaw, AJ Garrity, GZ Munoz, JR Haswell, S Sengupta, ... Nature communications 13 (1), 2833, 2022 | 20 | 2022 |
| Engineered primate L-methioninase for therapeutic purposes G Georgiou, E Stone, WC Lu US Patent 9,481,877, 2016 | 15 | 2016 |
| The B7-1 cytoplasmic tail enhances intracellular transport and mammalian cell surface display of chimeric proteins in the absence of a linear ER export motif YC Lin, BM Chen, WC Lu, CI Su, ZM Prijovich, WC Chung, PY Wu, ... PloS one 8 (9), e75084, 2013 | 13 | 2013 |
| Administration of kynurenine depleting enzymes for tumor therapy G Georgiou, E Stone, N Marshall, J Blazeck, WC Lu US Patent 9,975,959, 2018 | 11 | 2018 |
| Engineered primate L-methioninase for therapeutic purposes G Georgiou, E Stone, WC Lu US Patent 9,624,484, 2017 | 11 | 2017 |
| Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme J Blazeck, CS Karamitros, K Ford, C Somody, A Qerqez, K Murray, ... Nature catalysis 5 (10), 952-967, 2022 | 9 | 2022 |
| Administration of kynurenine depleting enzymes for tumor therapy G Georgiou, E Stone, N Marshall, J Blazeck, WC Lu US Patent 11,168,142, 2021 | 3 | 2021 |
| Design and selection of a synthetic operon WC Lu, AD Ellington ACS Synthetic Biology 3 (6), 410-415, 2014 | 3 | 2014 |
| Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria G Georgiou, E Stone, WC Lu US Patent 11,033,612, 2021 | 2 | 2021 |
| Evolved enzymes for cancer therapeutics and orthogonal systems WC Lu Ph.D. Disseration, 2013 | 2 | 2013 |
| Engineered primate L-methioninase for therapeutic purposes G Georgiou, E Stone, WC Lu US Patent 10,724,026, 2020 | 1 | 2020 |
| Engineered primate L-methioninase for therapeutic purposes GM Georgiou, E Stone, WC Lu United States Patent and Trademark Office, 2017 | 1 | 2017 |
